

Chong Kun Dang Pharmaceutical Company



"Better Life through Better Medicine"





Contents

- 01 Corporate Information
- 02 History
- 03 Sales Revenue & R&D Expenditure
- 04 Market Competitive Power
- 05 Worldwide Partnership
- 06 Pipeline

CORPORATE INFORMATION

Better Life through Better Medicine



Since 1941, Chong Kun Dang Pharmaceutical Corp. (CKD) has managed to lead Korean pharmaceutical industry and maintained its status as one of the top Korean pharmaceutical companies. From the development of generic drug to innovative drug, CKD is actively investing towards R&D to strengthen our presence not only in the domestic pharmaceutical market but also in the global market.

R&D and Manufacturing CKD has the capacity to research and develop drugs in broad areas: New Chemical Entity (NCE), Incrementally Modified Drug (IMD), and Biologics with a focus on antineoplastic, metabolic, immune and cardiovascular diseases. CKD also established a GMP approved manufactory and all products are produced under meticulous validation.


Sales & Marketing CKD is well-known for strong sales capability and marketing networks. More than 880 sales reps. and product managers, all well trained and dedicated, keep strong relationships with key opinion leaders in various fields, leading us to be the market leader in the Korean pharmaceutical market.

Global Partnership CKD has maintained close business relationships with numerous global partners such as MSD, Pfizer, Italfarmaco, Roche, Amgen, etc. Our mutual trust was built on our successful sales performance with partnered products (Januvia®, Prevenar13®, CKD Gliatilin®, Tamiflu®, Atozet®, Dilatrend®, Prolia®, etc.).

Overview

Establishment	1941. 5. 7
Capital	US\$ 22M
Business	Manufacturing & Sales of Pharmaceutical Products
Total assets	US\$ 620M (2017)
Net sales	US\$ 825M (2017)
Employees	2,006 (2017)

Location of Business Offices



CKD Business Group

*Currency : 1 USD = KRW 1,071

Chong Kun Dang Bio Corp.

Establishment	2001. 11. 12
Capital	US\$ 12.2M
Business	API & Intermediates from fermentation
Manufacturing Site	Ansan, Korea

Kyongbo Pharmaceutical Co. Ltd.

Establishment	1987. 3. 31
Capital	US\$ 11.2M
Business	API & generic drug business
Manufacturing Site	Asan, Korea

Chong Kun Dang Healthcare Corp.

Establishment	1996. 1. 5
Capital	US\$ 4.8M
Business	Manufacturing & Sales of health functional food
Manufacturing Site	Dangjin, Korea

HISTORY

Making the history of the global pharmaceutical industry

1941 Established "Goongbon Pharmacy" (Founder: Mr. Chong-Kun Lee)



1956 Registered as a corporation, "Chong Kun Dang Pharm. Corp."

1965 Established the first API synthesis facility in Korea

1968 Received FDA approval for the first time in the Korean pharmaceutical industry

1970 Exported the antibiotic APIs to the US, Japan and Southeast Asia

1972 Established Central Research Laboratories for the first time in the Korean pharmaceutical industry

1974 Established the largest fermentation facilities in Korea and supplied Tetracycline and Oxytetracycline

1976 Listed on the Korea stock exchange market



1980 Succeeded in fermenting Rifampicin, an anti-tuberculosis drug, for the 3rd time in the world. Obtained FDA approval for Tetracycline, Oxytetracycline

1986 Obtained KGMP approval for all dosage forms



1995 Reorganized CKD Research Institute into two labs, Technology Lab and New Drug Discovery Lab

1996 Took over Kyongbo Pharmaceutical Co.

1998 Constructed Cheonan GMP plant

2001 Split CKD into CKD Pharm and CKD Bio

2010 CKD Bio received US\$ 100M exports award



2012 Opened sales office in Vietnam

2013 CKD Holdings was newly established as a holding company in CKD group

2015 Established PT CKD-OTTO Pharmaceuticals, a joint venture in Indonesia

2004 Launched a new drug "Camtobell", anti-cancer drug

2011 Expanded and relocated central R&D center, "CKD research institute"

2014 Launched a new drug "Duvie", anti-diabetic drug


2018 Exported world's first 2nd generation EPO biosimilar 'CKD-11101' to Japan

SALES REVENUE & R&D EXPENDITURE


Excellent Growing Sales Performance

*Currency : 1 USD = KRW 1,071
Source : Annual Report 2017
Unit : mil. USD

Sales Revenue



R&D Expenditure




MARKET COMPETITIVE POWER


A company that has achieved numerous 'firsts' and 'bests'

*Currency : 1 USD = KRW 1,071
Source : IMS Sales Audit 2017
Unit : mil. USD


CKD Ranked 1st in Korean Prescription Market among Local Manufacturers in 2017



TOP10 Selling Products




No.1 in Local CVM Mfrs.



No.1 in Local Immunosuppressant Mfrs.



Sales by Therapeutic Class



WORLDWIDE PARTNERSHIP



Local License Partner



Overseas Business Partnership

OTTO

ACHIEVEMENT ON NEW CHEMICAL ENTITIES

Novel PPAR- γ agonist for diabetes

- Korea's 20th new drug, the 1st insulin sensitizer developed in Korea
- Launched in Korea in February 2014
- Significant blood glucose-lowering efficacy and safety profile
- Statistically significant improvements in metabolic syndrome and lipid profile
- Duvie[®] sales was approximately 11mil.USD (2017)




Novel topoisomerase-I inhibitor for small cell lung cancer and ovarian cancer

- Korea's 8th new drug, 3rd new anti-cancer drug
- Launched in Korea in 2004
- Significantly low rate of hematological adverse events (leukopenia, thrombocytopenia, anemia)



Pipeline



Better Life through Better Medicine

Headquarter:
8,Chungjeong-ro, Seodaemun-gu, Seoul, Korea

Manufacturing Site:
797-48 Manghyang-ro,Seonggeo-eup, Seobuk-gu,
Cheonan-si, Chungcheongnam-do, Korea

Research Institute:
315-20, Dongbaekjukjeon-daero, Giheung-gu,
Yongin-si, Gyeonggi-do, Korea

www.ckdpharm.com